CClinicalTrials.gg
CompletedNCT02033759Updated Jul 13, 2020Results posted

Patient Anxiety Associated With Lymphedema Surveillance Method

An interventional study of Bio-Impedance Testing and Anxiety Questionnaire in Anxiety, sponsored by Mercy Research. Completed at 1 site in United States. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-07-13.

Sponsored by Mercy Research · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Study summary

We propose to study the impact of BIA screening on anxiety and primary prevention strategies for lymphedema development among patients with recent surgery for breast cancer. Currently, professional societies recommend scheduled follow-up visits to screen for lymphedema after recovery from breast cancer (e.g., 6-week, 3-month, 6-month visits with a certified lymphedema therapist). Screening involves a discussion of lymphedema symptoms and risk reduction strategies, measurement of the affected limb with a tape measure, and physical inspection for physical changes consistent with lymphedema. In the proposed study, patients will be randomly assigned to the addition of BIA screening vs. usual care. At each screening visit, all patients will be assessed for their current lymphedema risk behaviors, as outlined by the National Lymphedema Network (7). To evaluate anxiety levels, all patients will be asked to fill out the Beck Anxiety Inventory, a validated screening tool used in prior studies of patients with breast cancer (8,9). This questionnaire will be administered at each follow-up lymphedema screening visit, and the baseline will be administered at the preoperative visit. For patients randomly assigned to BIA screening, this involves the placement of adhesive electrodes on the each wrist and an ankle, followed by connection of the electrodes to the BIA machine, which then uses a painless electrical impulse to measure impedance of flow and thus asymmetry in the extracellular lymphedema volume between the 2 upper limbs (6,10). Statistical analysis will involve comparison of lymphedema risk behaviors and anxiety levels between those patients with vs. without BIA screening.

02

Conditions studied

  • Anxiety

Keywords

  • Lymphedema
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women recently diagnosed with breast cancer Age 18 and older

Exclusion criteria

Exclusion Criteria:

  • Those women with a pacemaker
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Active comparator
    Traditional circumferential measurements

    Traditional screening with volumetric analysis Patient Anxiety Questionnaire

    Other: Anxiety Questionnaire · Other: Traditional Circumferential Measurements

  • Experimental
    Bio-Impedance Testing

    Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire

    Device: Bio-Impedance Testing · Other: Anxiety Questionnaire · Other: Traditional Circumferential Measurements

Interventions

  • DeviceBio-Impedance Testing

    Participants in the BIA Arm will also undergo bio-impedance testing with this device.

    Also known as: LTU-400 by Impedimed

  • OtherAnxiety Questionnaire

    21 item questionnaire

    Also known as: Beck Anxiety Inventory will be administered.

  • OtherTraditional Circumferential Measurements
05

What researchers measure

Primary outcomes

  1. Anxiety

    The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

    Time frame: 6 weeks post-op

  2. Anxiety

    The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

    Time frame: 3 months post-op

  3. Anxiety

    The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

    Time frame: 6 months post-op

06

Results

Posted May 27, 2020
Limitations and caveats
Our study used the Beck Anxiety Inventory, with its greater focus on physical symptoms of anxiety, and this approach may not have been as sensitive for identifying emotional distress when compared with other psychological tools.

Participant flow

Participant flow — Overall Study
MilestoneTraditional Circumferential MeasurementsBio-Impedance Testing
Started2221
Completed1919
Not completed32
Withdrew: Withdrawal by subject21
Withdrew: Protocol violation11

Outcome measures

PrimaryAnxiety

The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

Time frame:
6 weeks post-op
Reported as:
Mean · units on a scale
Anxiety
units on a scaleTraditional Circumferential MeasurementsBio-Impedance Testing
Anxiety7.1 (0 to 23)8.8 (0 to 31)
PrimaryAnxiety

The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

Time frame:
3 months post-op
Reported as:
Mean · units on a scale
Anxiety
units on a scaleTraditional Circumferential MeasurementsBio-Impedance Testing
Anxiety7.8 (0 to 26)10.1 (0 to 39)
PrimaryAnxiety

The Beck Anxiety Score is a measurement on a scale from 0 to 63 obtained by using the Beck Anxiety Inventory tool to assess symptoms of anxiety. A higher score correlates to increased anxiety whereas a lower score expresses a lower amount of anxiety.

Time frame:
6 months post-op
Reported as:
Mean · units on a scale
Anxiety
units on a scaleTraditional Circumferential MeasurementsBio-Impedance Testing
Anxiety5.1 (0 to 15)6.6 (0 to 20)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Traditional Circumferential Measurements—0/20 (0%)0/20 (0%)
Bio-Impedance Testing—0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Traditional Circumferential MeasurementsBio-Impedance TestingTotal
<=18 years000
Between 18 and 65 years131124
>=65 years6814
Sex: Female, Male
Sex: Female, Male(Participants)Traditional Circumferential MeasurementsBio-Impedance TestingTotal
Female191837
Male011
Region of Enrollment
Region of Enrollment(participants)Traditional Circumferential MeasurementsBio-Impedance TestingTotal
United States191938
Body Mass Index
Body Mass Index(BMI (kg/m^2) Average)Traditional Circumferential MeasurementsBio-Impedance TestingTotal
Mean30 (24 to 40)29 (21 to 42)30 (21 to 42)
Anxiety
Anxiety(units on a scale)Traditional Circumferential MeasurementsBio-Impedance TestingTotal
Mean7.2 (0 to 25)12.2 (0 to 34)9.6 (0 to 34)
07

Study locations

1 site
  • Mercy Clarkson/Clayton
    Creve Coeur, Missouri 63141, United States
08

References and documents

Individual participant data

Plan to share: Yes — POSTER PRESENTATION AT ACRM CONFERENCE CHICAGO NOV 2016

No publications or documents are linked to this record.

09

Registry details

Key details

Study ID
NCT02033759
Lead sponsor
Mercy Research
Responsible party
Sarah Stolker (Physical Therapist, Mercy Integrative Medicine) — Principal investigator
First posted
Jan 13, 2014
Start date
Jun 2014
Primary completion
Sep 2016
Completion
Mar 19, 2019
Results posted
May 27, 2020
Last update
Jul 13, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion